Vulvar Neoplasms clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
at UC Davis
Our lead scientists for Vulvar Neoplasms research studies include Tianhong Li, MD.
Last updated: